Clemson University

Other

Dan T Simionescu

Leslie Sierad

Narendra R Vyavahare

Agneta Simionescu

Richard Pascal, Iii

Jeremy J Mercuri

Christopher Delaney

Eliza Laine Shaw

George Fercana

Chris deBorde

Christopher deBorde

James Chow

Samuel G Rankin

M Keith Vinson

Marius Todor

Bioreactors and components of bioreactors are described as may be beneficially utilized in development and conditioning of cellular materials for study or implant. The bioreactors are modular, and components of the bioreactors can be easily assembled with alternatives provided to develop specific, predetermined conditioning environments for cellular materials (e.g., implantable tissue). By selection of one of multiple alternative compliance chambers, a bioreactor can be utilized to condition tissue in a low-pressure circuit (e.g., a pulmonary heart circuit), and by utilization of an alternative compliance chamber, the bioreactor can instead condition tissue in a high-pressure circuit (e.g., an aortic heart circuit).

Modular bioreactor, compliance chamber for a bioreactor, and cell seeding apparatus

Bioreactors and components of bioreactors are described as may be beneficially utilized in development and conditioning of cellular materials for study or implant. The bioreactors are modular and components of the bioreactors can be easily assembled with alternatives provided to develop specific, predetermined conditioning environments for cellular materials (e.g., implantable tissue). By selection of one of multiple alternative compliance chambers, a bioreactor can be utilized to condition tissue in a low pressure circuit (e.g., a pulmonary heart circuit), and by utilization of an alternative compliance chamber, the bioreactor can instead condition tissue in a high pressure circuit (e.g., an aortic heart circuit).

Systems and methods that establish a pressure differential across a tissue wall to encourage complete decellularization of the wall are described. The methods can be utilized for decellularization of blood vessel tissue including heart valves and surrounding tissues. The methods and systems can essentially completely decellularize the treated tissue segments. Systems can be utilized to decellularize one or multiple tissue segments at a single time.

Decellularization method and system and decellularized tissue formed thereby

Tissue holders that can be used for gripping natural or synthetic heart valves are described. The tissue holder can include a clamping mechanism and a spring and can be self-adjusting with regard to pressure applied to the tissue gripped in the holder. The tissue holder can be removably attached to systems for processing the tissues and can provide completely hands-free processing of a tissue from development or excisement to implantation and/or completion of testing.

Self-adjusting tissue holder

A hydrogel biomaterial that can be utilized as a nucleus pulposus replacement material is described. The hydrogel biomaterial can is an elastin-glycosaminoglycan-collagen composite hydrogel biomaterial that can mimic the biochemical and functional characteristics of the human nucleus pulposus. Methods for forming the hydrogel biomaterial are also described as are methods for use of the hydrogel biomaterial, one of which is as an in vivo nucleus pulposus replacement material, another of which is a scaffolding material for use in nucleus pulposus tissue engineering applications.

Shape-memory sponge hydrogel biomaterial

Disclosed is a medical device treated with a phenolic compound and a process for treating a device with the phenolic compound. For example, a collagen or elastin-based scaffold can be treated with pentagalloyl glucose (PGG). The treated scaffold can become resistant to glycoxidative stress associated with advanced glycation end products (AGEs) that are present in a hyperglycemic environments associated with diabetes mellitus. The treated scaffold can exhibit a reduced increase in stiffness as compared to an untreated scaffold. The treated scaffold can also exhibit reduced inflammation without negatively affecting the ability of the scaffold to remodel in vivo.

Treatment to render implants resistant to diabetes

A nucleus pulposus replacement is described that includes a containment balloon that can sequester synthetic and/or tissue engineered fill material(s) in the nucleus pulposus region of the IVD thus mitigating migration and expulsion of the fill materials. The containment balloon can be formed of a biocompatible material that includes the structural proteins elastin and collagen. The containment balloon is joined to a closure device that can be used to deliver a fill material, e.g., a hydrogel, to the interior of the containment balloon following implantation of the replacement device in the intervertebral disc area.

Tissue engineered nucleus pulposus replacement

A male fitting has a body that defines a fluid passage that extends through the body from a first end to a second end. The body may include a first portion adjacent to the first end, a second portion adjacent to the second end and a middle portion separating the first and second portions. The body may further define a slot between the middle portion and the second end. The slot extends at least partially circumferentially around the body. An actuating member may extend at least partially around the body. The actuating member may have at least one stop feature that engages with the body, and a retaining feature that is at least partially aligned with the slot. A spring disposed between the body and the actuating member may exert a force on the actuating member so as to position the retaining feature radially outward from the slot.

Male fitting with actuating retaining feature

A method and product are provided for the treatment of connective tissue weakened due to destruction of tissue architecture, and in particular due to elastin degradation. The treatment agents employ certain unique properties of phenolic compounds to develop a protocol for reducing elastin degradation, such as that occurring during aneurysm formation in vasculature. According to the invention, elastin can be stabilized in vivo and destruction of connective tissue, such as that leading to life-threatening aneurysms in vasculature, can be tempered or halted all together. The treatment agents can be delivered or administered acutely or chronically according to various delivery methods, including sustained release methods incorporating perivascular or endovascular patches, use of microsphere carriers, hydrogels, or osmotic pumps.

Elastin stabilization of connective tissue

A biomaterial useful for bioprostheses such as bioprosthetic heart valves is provided in which the fixed tissue has improved elastic properties. The high elastin-containing biomaterial is further characterized by having anisotropic properties wherein the biological material has a greater stiffness in one direction and a greater elasticity in a cross direction. For instance, the biological material has an elastin content of about 30% by weight. In one embodiment, the biological material is vena cava tissue.

Growing community of inventors

Central, SC, United States of America

Dan T Simionescu